Moreover, the combination of IL-6 with existing conventional diagnostic tools such as RMI score and ROMA or conventional biomarkers CA125 and HE4 improved the ability of the tests to identify patients with malignant ovaries (Table 3, Figs. 3,4). Here, IL6 is linked to cancer.